Mersana Therapeutics remains in a precarious financial position, characterized by a reliance on volatile, non-recurring milestone payments that have failed to offset persistent operational losses.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 2, 2026 | -$2.75+10.0% vs -$3.05 | — vs $5M |
Q4 2025 Nov 14, 2025 | -$1.51-4.9% vs -$1.44 | $11M-29.0% vs $16M |
Q3 2025 Aug 13, 2025 | -$4.87-29.9% vs -$3.75 | $3M-50.6% vs $6M |
Q2 2025 May 15, 2025 | -$4.75+1.3% vs -$4.81 | $3M-54.5% vs $6M |
Benchmark MRSN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mersana Therapeutics, Inc. (MRSN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.08 | $145.36M | -2.06 | 9.88% | -170.86% | -505.14% | — | |
| $18.28 | $2.3B | -5.56 | -4.26% | -386.32% | -87.98% | — | |
| $9.54 | $845.34M | -2.90 | 627.84% | -72.38% | -804.38% | — | |
| $7.15 | $297.74M | -2102.94 | 10.37% | 69.76% | — | — | |
| $59.83 | $9.16B | 21.60 | 87.32% | 55.22% | 72.3% | — | |
| $37.26 | $1.23B | -3.83 | -43.89% | -287.84% | -37.99% | — |
Mersana Therapeutics, Inc. (MRSN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mersana Therapeutics, Inc. (MRSN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jan 6, 2026·SEC
Nov 14, 2025·SEC
Nov 13, 2025·SEC
Get notified when MRSN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mersana Therapeutics, Inc. (MRSN) stock FAQ — growth, dividends, profitability & financials explained
Mersana Therapeutics, Inc. (MRSN) reported $33.2M in revenue over the trailing twelve months. Revenue was $40.5M in fiscal year 2024. That is 291% more than the $10.4M of fiscal year 2015.
Mersana Therapeutics, Inc. (MRSN) grew revenue by 9.9% in fiscal year 2024, compared with the prior fiscal year.
No. Mersana Therapeutics, Inc. (MRSN) reported a net loss of $70.1M over the trailing twelve months.
Mersana Therapeutics, Inc. (MRSN) had a return on equity (ROE) of -505.1% in fiscal year 2024. A negative ROE means the company lost money over the period.
Mersana Therapeutics, Inc. (MRSN) had negative free cash flow of $74.4M over the trailing twelve months.
